HLA-DRB1*03 allele is a significant predictor of anti-adalimumab antibodies formation in RA, HS, and IBD patients treated with anti-TNF therapies, contributing to variability in immunogenic responses. The gene discussed is HLA-DRB1; the disease is rheumatoid arthritis.